Loading company…
Patch Biosciences developed an AI platform for designing genetic medicines and gene therapies.
Patch Biosciences combines AI, synthetic biology, and molecular biology to design genetic medicine cargo and gene therapies. Founded in 2020 and based in New York, US, it was acquired by Ginkgo Bioworks in February 2024 from Andreessen Horowitz, Casdin Capital, and S32.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in